# A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

> **NCT04656184** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 84 (estimated)

## Conditions studied

- Kawasaki Disease

## Interventions

- **DRUG:** ANAKINRA
- **DRUG:** Intravenous immunoglobulin

## Key facts

- **NCT ID:** NCT04656184
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656184, "A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04656184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*